Commentary|Videos|November 26, 2024
Harnessing the Ability to Target NRG1 Fusions in NSCLC, Pancreatic Cancer
Author(s)Mary B. Beasley, MD
Mary B. Beasley, MD, discusses the prevalence of NRG1 fusions in non–small cell lung cancer and pancreatic cancer.
Advertisement
Episodes in this series
Advertisement
Related to this article
Sac-TMT plus pembrolizumab prolonged PFS over chemoimmunotherapy in PD-L1–negative nonsquamous lung cancer.
Adjuvant pembrolizumab continued to extend DFS in resected stage IB to IIIA NSCLC, though OS did not differ from placebo.
Longer DeLLphi-304 follow-up showed sustained OS, PFS, and response durability with tarlatamab in second-line small cell lung cancer.
Izalontamab brengitecan improved progression-free survival vs chemotherapy in EGFR-mutated lung cancer after a third-generation EGFR inhibitor.
Frontline savolitinib plus osimertinib improved progression-free survival vs osimertinib alone in EGFR-mutated, MET-overexpressing lung cancer.
The FDA granted breakthrough therapy designation to enzomenib for relapsed/refractory acute leukemia with a KMT2A rearrangement.
In SAFFRON, the oral EGFR/MET inhibitor pairing extended survival over platinum/pemetrexed in MET-driven lung cancer that progressed on osimertinib.
Adding LK101 to tislelizumab-based first-line maintenance yielded early antitumor activity and signs of immune activation in advanced NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
Breaking Down Key Lung Cancer Data at ESMO 2026 With Drs Santos and Halmos
2
FDA Receives BLA for Etentamig in R/R Multiple Myeloma
3
T-DXd Gains EU Approval in Residual HER2+ Early Breast Cancer
4
Basser Center for BRCA Awards 2026 Global Prize to Judy Garber
5